EOLS - NASDAQ

Evolus, Inc.

EOLS·NASDAQ

$6.03

-2.3%

HealthcareDrug Manufacturers - Specialty & Generic

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$397.10M

EPS-0.8000

P/E Ratio-7.54

Earnings Date08/04/2026

225.87M

Assets

-3%

3Y+27.0%

5Y+8.0%

10Y+191.0%

248.97M

Total Liabilities

10%

3Y+56.0%

5Y-12.0%

10Y+194.0%

-23.11M

Total Equity

-518%

3Y-225.0%

5Y-68.0%

10Y+225.0%

Evolus, Inc. Funding & Solvency Profile

EOLS · NASDAQ

Current Assets

Cash & Cash Equivalents53.83M

Net Receivables54.70M

Inventory26.96M

Other Current Assets7.43M

Total Current Assets143 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets69.25M

Long-Term Investments0.00

Other Non-Current Assets13.70M

Total Non-Current Assets14 M

Total Assets

225.87M

Financial Health Analysis

Current Ratio

1.90x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Working Capital

68 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

63% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Evolus, Inc. Balance Sheet

EOLS • NASDAQ

Evolus, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	53.8M	87M	62.8M	53.9M	146.3M	102.6M	109.9M	93.2M	0.0	0.0	4M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	5M	19.9M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	53.8M	87M	62.8M	53.9M	146.3M	107.6M	129.8M	93.2M	0.0	0.0	4M
Net Receivables	54.7M	47.7M	30.5M	22.4M	14.7M	9.7M	10.7M	0.0	72.6M	0.0	0.0
Accounts Receivables	54.7M	47.7M	30.5M	22.4M	14.7M	9.7M	10.7M	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	72.6M	0.0	0.0
Inventory	27M	12.2M	11M	18.9M	1.8M	3.4M	6.4M	0.0	0.0	0.0	0.0
Prepaids	0.0	3.3M	5.7M	3.9M	5.1M	4.8M	5.3M	1.2M	185K	24K	17K
Other Current Assets	7.4M	1.2M	2.4M	1.7M	11M	2.2M	0.0	1.2M	0.0	187K	4M
Total Current Assets	142.9M	151.3M	112.4M	100.8M	178.8M	127.6M	152.2M	94.3M	72.8M	211K	4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	10.4M	7.9M	4.6M	4.1M	4.7M	5M	0.0	0.0	0.0	0.0
Goodwill	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M	21.2M
Intangible Assets	48M	48.8M	47.1M	48.6M	50.6M	55.3M	59.6M	56.1M	56.1M	56.1M	56.1M
Goodwill & Intangible Assets	69.2M	70M	68.3M	69.8M	71.8M	76.5M	80.8M	77.3M	77.3M	77.3M	77.3M
Other Non-Current Assets	13.7M	858K	409K	2.8M	2.8M	240K	2.4M	221K	2.1M	0.0	0.0
Total Non-Current Assets	83M	81.2M	76.6M	77.2M	78.7M	81.5M	88.2M	77.5M	79.4M	77.3M	77.3M
Total Assets	225.9M	232.6M	189M	178M	257.5M	209.1M	240.4M	171.8M	152.2M	77.5M	81.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	23.4M	20.5M	4.3M	15.4M	11.4M	13.1M	9.3M	1.6M	445K	2.9M	230K
Accounts Payable	23.4M	9.2M	4.3M	8.9M	6.1M	9.6M	5.8M	1.6M	445K	2.9M	230K
Other Payables	0.0	11.2M	0.0	6.5M	5.3M	3.4M	3.5M	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	26.3M	13.4M	20.8M	37.1M	69.4M	12.3M	2.6M	977K	675K	1.7M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	93.5M	0.0	0.0	211.3M	59.8M	46.2M
Capital Lease Obligations (Current)	2.5M	1.7M	1.4M	1.3M	1.3M	1.2M	1.2M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	14.5M	11M	9M	7.9M	3.1M	1.7M	0.0	0.0	0.0	0.0
Other Current Liabilities	49.4M	0.0	18.2M	0.0	0.0	0.0	0.0	1.1M	0.0	0.0	0.0
Total Current Liabilities	75.3M	63M	48.3M	46.5M	57.7M	180.2M	24.4M	5.3M	212.7M	63.3M	48.1M
NON-CURRENT LIABILITIES
Long Term Debt	146.1M	121.5M	120.4M	71.9M	71.2M	40.5M	91.5M	16.9M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	28K	6K	27K	22K	40K	25K	0.0	15.1M	15M	21.2M	21.2M
Other Non-Current Liabilities	21.2M	35.8M	36.2M	39.9M	44.4M	58.1M	41.2M	50.2M	38K	44K	46K
Total Non-Current Liabilities	173.7M	164.1M	161.4M	113M	117.9M	101.8M	136.5M	82.2M	15M	21.3M	21.2M
Capital Lease Obligations	8.9M	8.5M	6.2M	2.5M	3.5M	4.4M	5.1M	0.0	0.0	0.0	0.0
Total Liabilities	249M	227M	209.7M	159.5M	175.6M	282M	161M	87.5M	227.8M	84.6M	69.3M
SHAREHOLDERS' EQUITY
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	0.0	0.0	0.0
Additional Paid-In Capital	638.1M	615.8M	538.7M	516.1M	504.8M	303.1M	292.5M	207.4M	0.0	59.7M	58.7M
Retained Earnings	-661M	-609.4M	-559M	-497.3M	-422.9M	-376.1M	-213.1M	-123M	-75.5M	-66.8M	-46.7M
Accumulated Other Comprehensive Income/Loss	-156K	-905K	-427K	-337K	0.0	0.0	6K	0.0	0.0	0.0	0.0
Total Stockholders' Equity	-23.1M	5.5M	-20.7M	18.5M	81.9M	-73M	79.5M	-123M	-75.5M	-7.1M	12M
Total Equity	-23.1M	5.5M	-20.7M	18.5M	81.9M	-73M	79.5M	-123M	-75.5M	-7.1M	12M
SUMMARY
Total Liabilities & Equity	225.9M	232.6M	189M	178M	257.5M	209.1M	240.4M	-35.6M	152.2M	77.5M	81.3M
Total Investments	0.0	0.0	0.0	0.0	0.0	5M	19.9M	0.0	0.0	0.0	0.0
Total Debt	155M	130M	126.5M	74.4M	74.7M	138.3M	96.5M	16.9M	211.3M	59.8M	46.2M
Net Debt	101.2M	43M	63.7M	20.5M	-71.5M	35.8M	-13.3M	-76.3M	211.3M	59.8M	42.2M
Shares Outstanding	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784	64,819,784

SEC Filings

EOLS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 13, 2026	March 13, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 08, 2025	September 08, 2025	2025	View Filing

Showing 1 to 10 of 149 filings

Related Guides

Blog Categories

Continue your EOLS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.